People: Merck & Co Inc (MRK.N)

Summary

Name	Age	Since	Current Position
Kenneth Frazier	58	2011	Chairman of the Board, President, Chief Executive Officer
Peter Kellogg	56	2009	Chief Financial Officer, Executive Vice President
Clark Golestani	46	2012	Executive Vice President, Chief Information Officer
Michael Holston	50	2012	Executive Vice President, Chief Ethics and Compliance Officer
Bruce Kuhlik	56	2009	Executive Vice President, General Counsel
Mirian Graddick-Weir	58	2009	Executive Vice President - Human Resources
Willie Deese	57	2009	Executive Vice President, President - Merck Manufacturing Division
Richard DeLuca	50	2011	Executive Vice President, President - Merck Animal Health
Cuong Do	46	2011	Executive Vice President, Chief Strategy Officer
Bridgette Heller	51	2010	Executive Vice President, President - Merck Consumer Care
Roger Perlmutter	61	2013	Executive Vice President, President - Merck Research Laboratories
Michael Rosenblatt	65	2009	Executive Vice President, Chief Medical Officer
Adam Schechter	48	2010	Executive Vice President, President - Global Human Health
John Canan	56	2009	Senior Vice President - Finance, Global Controller
Adele Ambrose	56	2009	Senior Vice President, Chief Communications Officer
William Harrison	68	2009	Lead Independent Director
Leslie Brun	60	2008	Independent Director
Thomas Cech	64	2009	Independent Director
Thomas Glocer	52	2007	Independent Director
C. Robert Kidder	68	2005	Independent Director
Rochelle Lazarus	65	2004	Independent Director
Carlos Represas	68	2009	Independent Director
Patricia Russo	60	1995	Independent Director
Craig Thompson	58	2008	Independent Director
Wendell Weeks	53	2004	Independent Director
Peter Wendell	61	2003	Independent Director

» Insider Trading

Biographies

Name	Description
Kenneth Frazier	Mr. Kenneth C. Frazier is Chairman of the Board, President, Chief Executive Officer of Merck & Co., Inc. He has been Chairman since December 2011, President since May 2010, and Chief Executive Officer since January 2011, Merck & Co., Inc. Mr. Frazier previously served as Executive Vice President and President, Global Human Health of the Company (since November 2009) and Merck Sharp & Dohme Corp. (2007 to 2009). He is Director, Exxon Mobil Corporation, The Pennsylvania State University and Cornerstone Christian Academy in Philadelphia, P.A.; Member, Council on Foreign Relations, the Council of the American Law Institute and the American Bar Association. Mr. Frazier served as Executive Vice President and General Counsel (November 2006 to August 2007), and Senior Vice President and General Counsel (December 1999 to November 2006) of Merck Sharp & Dohme Corp. (formerly known as Merck & Co., Inc.).
Peter Kellogg	Mr. Peter N. Kellogg is Chief Financial Officer, Executive Vice President of Merck & Co., Inc. He is responsible for the Company’s worldwide financial organization, investor relations, corporate development and licensing, and the Company’s joint venture relationships. Since August 2007 — Executive Vice President and Chief Financial Officer, Merck & Co., Inc. — responsible for the Company’s worldwide financial organization, investor relations, corporate development and licensing, and the Company’s joint venture relationships. Prior to August 2007, Mr. Kellogg was Executive Vice President, Finance and Chief Financial Officer of Biogen Idec (a biotechnology company) from the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in November 2003.
Clark Golestani	Mr. Clark Golestani is Executive Vice President, Chief Information Officer of Merck & Co., Inc. He is responsible for Merck’s global information technology (IT). His experience includes August 2008 — Vice President, Merck Research Laboratories Information Technology, Merck & Co., Inc. — responsible for global IT for Merck’s Research & Development division, including Basic Research, PreClinical, Clinical and Regulatory & from November 2006 — Vice President, Corporate Information Technology, Merck & Co., Inc. — responsible for global IT supporting Finance, Human Resources, Procurement, Legal, Public Affairs, Site Services, Real Estate, and Shared Business Services operations
Michael Holston	Mr. Michael J. Holston is Executive Vice President, Chief Ethics and Compliance Officer of Merck & Co Inc. Holston most recently served as executive vice president and general counsel for Hewlett-Packard Company, where he oversaw compliance, government affairs, privacy, ethics operations and legal affairs. Prior to his role with Hewlett-Packard, Holston was a partner in the litigation practice at Morgan, Lewis & Bockius LLP, where he served as external counsel to Merck on matters such as product litigation, government investigations and compliance with healthcare laws and regulations. Before joining Morgan Lewis, he served as a prosecutor in the criminal division of the U.S. Attorney's Office for the Eastern District of Pennsylvania. Holston received his J.D. from Villanova University School of Law, Villanova, Penn. and a B.S.M.E. from the University of Notre Dame, South Bend, Indiana. He also is a fellow in the American College of Trial Lawyers.
Bruce Kuhlik	Mr. Bruce N. Kuhlik is an Executive Vice President, General Counsel of Merck & Co., Inc. He is responsible for legal, communications, and public policy functions and The Merck Company Foundation (a not-for-profit charitable organization affiliated with the Company). Since January 2008 — Executive Vice President and General Counsel, Merck & Co., Inc. — responsible for legal, communications, and public policy functions and The Merck Company Foundation (a not-for-profit charitable organization affiliated with the Company). Since August 2007 — Senior Vice President and General Counsel, Merck & Co., Inc. — responsible for legal, communications, and public policy functions and The Merck Company Foundation (a not-for-profit charitable organization affiliated with the Company). since May 2005 — Vice President and Associate General Counsel, Merck & Co., Inc. — primary responsibility for the Company’s Vioxx litigation defense.
Mirian Graddick-Weir	Dr. Mirian M. Graddick-Weir is Executive Vice President - Human Resources of Merck & Co., Inc. She is responsible for the Global Human Resources organization. Since January 2008 — Executive Vice President, Human Resources, Merck & Co., Inc. — responsible for the Global Human Resources organization. Since September 2006 — Senior Vice President, Human Resources, Merck & Co., Inc.
Willie Deese	Mr. Willie A. Deese is Executive Vice President, President - Merck Manufacturing Division of Merck & Co., Inc. He is responsible for the Company’s global manufacturing, procurement, and distribution and logistics functions. Since January 2008 — Executive Vice President and President, Merck Manufacturing Division, Merck & Co., Inc. — responsible for the Company’s global manufacturing, procurement, and distribution and logistics functions. Since May 2005 — President, Merck Manufacturing Division, Merck & Co., Inc. — responsible for the Company’s global manufacturing, procurement, and operational excellence functions.
Richard DeLuca	Mr. Richard R. DeLuca, Jr., is Executive Vice President, President - Merck Animal Health of Merck & Co Inc. He is responsible for the Merck Animal Health organization. Prior to September 2011, Mr. DeLuca was Chief Financial Officer, Becton Dickinson Biosciences (a medical technology company) since 2010 and President, Wyeth’s Fort Dodge Animal Health division from 2007 to 2010. He served as Chief Operating Officer, Fort Dodge from 2006 to 2007 and Executive Vice President and Chief Financial Officer from 2002 to 2006.
Cuong Do	Mr. Cuong Viet Do is Executive Vice President, Chief Strategy Officer of Merck & Co Inc. He is responsible for the formulation and execution of the Company’s long term strategic plan. Prior to October 2011, Mr. Do was Senior Vice President, Corporate Strategy and Business Development, TE Connectivity (a global company that designs, manufactures and markets products for customers in a variety of industries) from 2009 to 2011 and Senior Vice President and Chief Strategy Officer, Lenovo (a personal technology company) from 2006 to 2009.
Bridgette Heller	Ms. Bridgette P. Heller is an Executive Vice President, President - Merck Consumer Care of Merck & Co., Inc. She is responsible for the Merck Consumer Care organization. Prior to March 2010, Ms. Heller was President, Johnson & Johnson’s Baby Global Business Unit from 2007 to 2010 and President for Global Baby, Kids and Wound Care from 2005 to 2007.
Roger Perlmutter	Dr. Roger M. Perlmutter, M.D., Ph.D., has been appointed as Executive Vice President, President - Merck Research Laboratories of Merck & Co Inc. effective April 15, 2013. Dr. Perlmutter was executive vice president and head of R&D at Amgen Inc. from January 2001 to February 2012. During his tenure, Dr. Perlmutter oversaw the development and subsequent approval of a number of novel biologic and small molecule medicines in the areas of cancer, endocrinology, hematology, inflammation and osteoporosis. Prior to joining Amgen, he was executive vice president of worldwide basic research and preclinical development at Merck. He joined Merck as a senior vice president in February 1997. Before assuming leadership roles in industry, Dr. Perlmutter was a professor in the Departments of Immunology, Biochemistry and Medicine at the University of Washington, where he also served as chairman of the Department of Immunology and was a Howard Hughes Medical Institute investigator. He is a Fellow of the American Academy of Arts and Sciences and an elected Fellow of the American Association for the Advancement of Science. Dr. Perlmutter graduated from Reed College in 1973 and received his M.D. and Ph.D. degrees from Washington University in St. Louis in 1979.
Michael Rosenblatt	Dr. Michael Rosenblatt, M.D., is Executive Vice President, Chief Medical Officer of Merck & Co., Inc. He is responsible for the Company’s primary voice to the global medical community on critical issues such as patient safety and oversight for the Company’s Global Center for Scientific Affairs. Prior to December 2009, Dr. Rosenblatt was the Dean of Tufts University School of Medicine since 2003.
Adam Schechter	Mr. Adam H. Schechter is Executive Vice President, President - Global Human Health of Merck & Co., Inc. He is responsible for the Company’s pharmaceutical and vaccine worldwide business. Since November 2009 — President, Global Human Health, U.S. Market-Integration Leader, Merck & Co., Inc. — commercial responsibility in the United States for the Company’s portfolio of prescription medicines. Leader for the integration efforts for the Merck/Schering-Plough merger across all divisions and functions. Since August 2007 — President, Global Pharmaceuticals, Global Human Health, Merck & Co., Inc. — global responsibilities for the Company’s atherosclerosis/cardiovascular, diabetes/obesity, oncology, specialty/neuroscience, respiratory, bone, arthritis and analgesia franchises as well as commercial responsibility in the United States for the Company’s portfolio of prescription medicines. Since July 2006 — President, U.S. Human Health, Merck & Co., Inc. — commercial responsibility in the United States for the Company’s portfolio of prescription medicines.
John Canan	Mr. John Canan is Senior Vice President - Finance, Global Controller of Merck & Co., Inc. He is responsible for the Company’s global controller’s organization including all accounting, controls, external reporting and financial standards and policies. Since January 2008 — Senior Vice President and Controller, Merck & Co., Inc. — responsible for the Corporate Controller’s Group. Since September 2006 — Vice President, Controller, Merck & Co., Inc. — responsible for the Corporate Controller’s Group.
Adele Ambrose	Ms. Adele D. Ambrose is Senior Vice President, Chief Communications Officer of Merck & Co., Inc. She is responsible for the Global Communications organization. Since December 2007 — Vice President and Chief Communications Officer, Old Merck — responsible for the Global Communications organization.
William Harrison	Mr. William B. Harrison is Lead Independent Director of Merck & Co Inc. He is Retired Chairman of the Board, JPMorgan Chase & Co., since December 31, 2006, prior to which he was Chairman from November 2001 and Chief Executive Officer from December 2000 until December 2005. He is Chairman, Cadence Bancorp LLC (formerly Community Bancorp LLC) since 2010 (bank holding company); Director, Aurora Capital Group since 2007 (private equity firm), Cousins Properties Incorporated since 2006 (diversified development company), Lincoln Center for the Performing Arts since 2006, RecoverCare LLC since 2009 (healthcare company) and The University of North Carolina Endowment Fund; Member, The Business Council, Board of Overseers of Memorial Sloan-Kettering Cancer Center and the National September 11 Memorial Museum Foundation. Mr. Harrison was a director of Merck Sharp & Dohme Corp. (formerly known as Merck & Co., Inc.) from 1999 to November 2009.
Leslie Brun	Mr. Leslie A. Brun is an Independent Director of Merck & Co., Inc . He is Chairman and Chief Executive Officer, Sarr Group, LLC since March 2006, prior to which he was Chairman Emeritus of Hamilton Lane from 2003 to March 2006. He is Non-Executive Chairman of the Board, Automatic Data Processing, Inc. since 2003 (global provider of business outsourcing solutions) and Broadridge Financial Solutions, Inc. since 2011 (investment consulting service provider); Director, NXT Capital, Inc. (a private financing solutions company); Member, Council on Foreign Relations. Mr. Brun was a director of Merck Sharp & Dohme Corp. (formerly known as Merck & Co., Inc.) from 2008 to November 2009. In deciding to nominate Mr. Brun, the Board considered his finance, management, investment banking, commercial banking and financial advisory experience, as well as his track record of achievement and sound judgment as demonstrated by his history as the Chairman and CEO of Sarr Group LLC (investment holding company), and former Chairman Emeritus, Chairman and founder of Hamilton Lane (a advisory and management firm).
Thomas Cech	Dr. Thomas R. Cech is an Independent Director of Merck & Co., Inc. He has been Investigator, Howard Hughes Medical Institute, and President from January 2000 to March 2009; Faculty, University of Colorado since 1978. He is Trustee, Grinnell College; Member, National Academy of Sciences. Dr. Cech was a director of Merck Sharp & Dohme Corp. (formerly known as Merck & Co., Inc.) from May to November 2009.
Thomas Glocer	Mr. Thomas H. Glocer is an Independent Director of Merck & Co Inc. He is Retired Chief Executive Officer, Thomson Reuters Corporation from April 2008 to December 2011, prior to which he was Chief Executive Officer of Reuters Group PLC from July 2001 to April 2008. He is Director, Partnership for New York City and Council on Foreign Relations; Member, International Business Council of the World Economic Forum, President’s Council on International Activities at Yale University, European Business Leaders Council, International Advisory Board of British American Business Inc., Madison Council of the Library of Congress, The Business Council, Advisory Board of the Judge Institute of Management at Cambridge University and the Columbia College Board of Visitors. Mr. Glocer was also a director of Merck Sharp & Dohme Corp. (formerly known as Merck & Co., Inc.) from 2007 to November 2009, Reuters Group PLC from 2000 to 2008 and Thomson Reuters Corporation from 2008 to 2011.
C. Robert Kidder	Mr. C. Robert Kidder is an Independent Director of Merck & Co., Inc. Former Chairman and Chief Executive Officer, 3Stone Advisors LLC from August 2006 to April 2011. Mr. Kidder was a Principal of Stonehenge Partners, Inc. from April 2004 to July 2006. He is Director, Morgan Stanley since 1994 (investment bank) and Microvi Biotech Inc. since 2008 (water filtration company); Board of Trustees, Nationwide Children’s Hospital (Columbus) since 1998, Ohio University since 2003 and Wexner Center Foundation since 1999. Mr. Kidder was Chairman of the Board of Directors, Chrysler Group LLC from 2009 to 2011.
Rochelle Lazarus	Ms. Rochelle B. Lazarus is an Independent Director of Merck & Co., Inc. She is Chairman, Ogilvy & Mather Worldwide, since January 1, 2009, prior to which she was Chairman and Chief Executive Officer from 1996 to 2008. She is Director, General Electric since 2000 (diversified technology, media and financial services company), Partnership for New York City and World Wildlife Fund. Trustee, New York Presbyterian Hospital since 1995, American Museum of Natural History since 2003 and Lincoln Center for the Performing Arts. Member, Board of Overseers, Columbia Business School since 1993, The Business Council, Council on Foreign Relations, and President’s Council on International Activities at Yale University. Ms. Lazarus was a director of Merck Sharp & Dohme Corp. (formerly known as Merck & Co., Inc.) from 2004 to November 2009.
Carlos Represas	Mr. Carlos Eduardo Represas is an Independent Director of Merck & Co., Inc. He is Retired Executive Vice President—Head of the Americas, Nestlé, S.A., Switzerland from 1994 to 2004. He is Retired Chairman, Nestlé Group Mexico, from 1983 to 2010. Non-Executive Chairman, Bombardier Latin America since 2012. Director, Bombardier Inc. since 2004 (aerospace & transportation company), Swiss Re Group and Swiss Re America Holding Corporation since 2010 (reinsurance and insurance companies); Board Member, Mexican Health Foundation since 1985 (not-for-profit private organization); Chairman of the Board of Trustees, National Institute of Genomic Medicine, Ministry of Health, Mexico since 2004; Member, Latin America Business Council and the Dean’s Advisory Board, Harvard School of Public Health. Mr. Represas was a director of Merck Sharp & Dohme Corp. (formerly known as Merck & Co., Inc.) from February to November 2009 and served on the board of Vitro S.A.B. de C.V. from 1998 to 2008 (glass manufacturing company).
Patricia Russo	Ms. Patricia F. Russo is an Independent Director of Merck & Co. Inc. She is Retired Chief Executive Officer and Director, Alcatel-Lucent from December 2006 through September 2008. Ms. Russo served as Chairman from 2003 to 2006 and Chief Executive Officer and President from 2002 to 2006 of Lucent Technologies Inc. until its merger with Alcatel. She is Director, Alcoa Inc. since 2008 (producer and manager of aluminum), Hewlett-Packard Company since 2011 (a technology company) and Lead Director, General Motors Company since 2009 (auto manufacturer); Chairman, Partnership For a Drug-Free America since 2010; Member, The Business Council, The Economic Club of New York and The Conference Board.
Craig Thompson	Mr. Craig B. Thompson is an Independent Director of Merck & Co. Inc. He is President and Chief Executive Officer of Memorial Sloan-Kettering Cancer Center since November 2010. Dr. Thompson was Professor of Medicine at the University of Pennsylvania School of Medicine from July 1999 to November 2011 and Director of the Abramson Cancer Center from 2006 to November 2010. Director, American Association for Cancer Research; Fellow, American Academy of Arts and Sciences; Member, Medical Advisory Board of the Howard Hughes Medical Institute and The National Academy of Sciences and its Institute of Medicine.
Wendell Weeks	Mr. Wendell P. Weeks is an Independent Director of Merck & Co., Inc. He is President since December 2010 and Chairman and Chief Executive Officer, Corning Incorporated, since April 2007, prior to which he was President and Chief Executive Officer from April 2005 to April 2007, and President and Chief Operating Officer from April 2002 to April 2005. He is Director, Corning Incorporated since 2000; Trustee, Lehigh University since 2006. Mr. Weeks was a director of Merck Sharp & Dohme Corp. (formerly known as Merck & Co., Inc.) from 2004 to November 2009.
Peter Wendell	Mr. Peter C. Wendell is an Independent Director of Merck & Co., Inc. He was Managing Director, Sierra Ventures for five years; Senior Advisor and Director, WestBridge Crossover Fund, LLC; Retired Chairman and Director, Princeton University Investment Co. since June 30, 2008, prior to which he was Chairman from July 1, 2003 and Director from July 1, 1998. Faculty, Stanford University Graduate School of Business since July 1, 1990. Charter Trustee Emeritus and Board officer, Princeton University; Mr. Wendell was also a director of Merck Sharp & Dohme Corp. (formerly known as Merck & Co., Inc.) from 2003 to November 2009.

Basic Compensation

Name	Fiscal Year Total
Kenneth Frazier	13,347,700
Peter Kellogg	5,369,260
Clark Golestani	--
Michael Holston	--
Bruce Kuhlik	3,975,180
Mirian Graddick-Weir	--
Willie Deese	--
Richard DeLuca	--
Cuong Do	--
Bridgette Heller	--
Roger Perlmutter	--
Michael Rosenblatt	--
Adam Schechter	6,539,900
John Canan	--
Adele Ambrose	--
William Harrison	--
Leslie Brun	--
Thomas Cech	--
Thomas Glocer	--
C. Robert Kidder	--
Rochelle Lazarus	--
Carlos Represas	--
Patricia Russo	--
Craig Thompson	--
Wendell Weeks	--
Peter Wendell	--

As Of 30 Dec 2011

Options Compensation

Name	Options	Value
Kenneth Frazier	789,066	412,878
Peter Kellogg	2	0
Clark Golestani	0	0
Michael Holston	0	0
Bruce Kuhlik	0	0
Mirian Graddick-Weir	0	0
Willie Deese	0	0
Richard DeLuca	0	0
Cuong Do	0	0
Bridgette Heller	0	0
Roger Perlmutter	0	0
Michael Rosenblatt	0	0
Adam Schechter	0	0
John Canan	0	0
Adele Ambrose	0	0
William Harrison	0	0
Leslie Brun	0	0
Thomas Cech	0	0
Thomas Glocer	0	0
C. Robert Kidder	0	0
Rochelle Lazarus	0	0
Carlos Represas	0	0
Patricia Russo	0	0
Craig Thompson	0	0
Wendell Weeks	0	0
Peter Wendell	0	0

Insider Trading

Name	Shares Traded	Price
HELLER BRIDGETTE P	5,404	$46.15
SCHECHTER ADAM H	5,488	$44.98
DEESE WILLIE A	14,631	$0.00
ROSENBLATT MICHAEL	2,323	$44.98
HELLER BRIDGETTE P	60,024	$33.49
FRAZIER KENNETH C	16,133	$44.98
GOLESTANI CLARK	2,239	$0.00
KELLOGG PETER N	19,354	$44.98
GOLESTANI CLARK	835	$44.98
HELLER BRIDGETTE P	29,860	$0.00
GRADDICK-WEIR MIRIAN M	22,096	$0.00
AMBROSE ADELE D	1,335	$44.98
KELLOGG PETER N	37,325	$0.00
HELLER BRIDGETTE P	15,483	$44.98
GRADDICK-WEIR MIRIAN M	11,458	$44.98
ROSENBLATT MICHAEL	4,479	$0.00
CANAN JOHN	1,669	$44.98
SCHECHTER ADAM H	12,188	$0.00
DEESE WILLIE A	6,588	$44.98
KUHLIK BRUCE N	17,186	$44.98
HELLER BRIDGETTE P	54,532	$45.08
FRAZIER KENNETH C	35,832	$0.00
CANAN JOHN	4,479	$0.00
KUHLIK BRUCE N	33,144	$0.00
AMBROSE ADELE D	3,583	$0.00

» Full list on Insider Trading

People: Merck & Co Inc (MRK.N)

Related Topics:

Summary

Biographies

Basic Compensation

Options Compensation

Related Topics: